EA201171109A1 - NEW COMPOSITION OF THE DELAYED RELEASE OF COMPOUNDS SELECTED FROM THE CLASS OF MINORALEXANTS OF CENTRAL ACTION - Google Patents

NEW COMPOSITION OF THE DELAYED RELEASE OF COMPOUNDS SELECTED FROM THE CLASS OF MINORALEXANTS OF CENTRAL ACTION

Info

Publication number
EA201171109A1
EA201171109A1 EA201171109A EA201171109A EA201171109A1 EA 201171109 A1 EA201171109 A1 EA 201171109A1 EA 201171109 A EA201171109 A EA 201171109A EA 201171109 A EA201171109 A EA 201171109A EA 201171109 A1 EA201171109 A1 EA 201171109A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sustained release
combination
minoralexants
class
compounds selected
Prior art date
Application number
EA201171109A
Other languages
Russian (ru)
Inventor
Динеш Шантилал Пател
Сачин Динеш Пател
Шашикант Прабхудас Курани
Original Assignee
Динеш Шантилал Пател
Сачин Динеш Пател
Шашикант Прабхудас Курани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Динеш Шантилал Пател, Сачин Динеш Пател, Шашикант Прабхудас Курани filed Critical Динеш Шантилал Пател
Publication of EA201171109A1 publication Critical patent/EA201171109A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Abstract

Раскрытое изобретение обеспечивает новые фармацевтические препараты замедленного высвобождения и способ получения таких композиций Толперизона и/или Эперизона и/или их фармацевтически приемлемых солей. Данное изобретение обеспечивает состав замедленного высвобождения Толперизона и Эперизона или отдельно, или в комбинации, или иным образом в комбинации с другими лекарствами, выбранными из классов, таких как обезболивающие, жаропонижающие, нейропротекторные средства, другие миорелаксанты, которые могут быть составлены либо в фиксированной дозе, либо как комбинированный набор для перорального введения. Композиция пригодна для введения один раз в день млекопитающим и обеспечивает замедленное и пролонгированное высвобождение лекарства вплоть до 24 ч, что содействует снижению частоты введения лекарства. Композиция содержит терапевтически эффективное количество активного вещества, полимеры, замедляющие высвобождение, и другие фармацевтически приемлемые наполнители.The disclosed invention provides novel sustained release pharmaceutical formulations and a process for preparing such compositions of Tolperisone and/or Eperisone and/or their pharmaceutically acceptable salts. This invention provides a sustained release formulation of Tolperisone and Eperisone either alone or in combination or otherwise in combination with other drugs selected from classes such as painkillers, antipyretics, neuroprotectives, other muscle relaxants, which can be formulated either in a fixed dose, or as a combination kit for oral administration. The composition is suitable for once-daily administration to mammals and provides delayed and sustained release of the drug up to 24 hours, which helps to reduce the frequency of drug administration. The composition contains a therapeutically effective amount of the active substance, release retardant polymers, and other pharmaceutically acceptable excipients.

EA201171109A 2009-03-09 2010-03-09 NEW COMPOSITION OF THE DELAYED RELEASE OF COMPOUNDS SELECTED FROM THE CLASS OF MINORALEXANTS OF CENTRAL ACTION EA201171109A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN522MU2009 2009-03-09
PCT/IN2010/000137 WO2010103544A2 (en) 2009-03-09 2010-03-09 A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants

Publications (1)

Publication Number Publication Date
EA201171109A1 true EA201171109A1 (en) 2012-03-30

Family

ID=42728892

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201171109A EA201171109A1 (en) 2009-03-09 2010-03-09 NEW COMPOSITION OF THE DELAYED RELEASE OF COMPOUNDS SELECTED FROM THE CLASS OF MINORALEXANTS OF CENTRAL ACTION

Country Status (5)

Country Link
EP (1) EP2405900A2 (en)
CN (1) CN102438597A (en)
EA (1) EA201171109A1 (en)
GE (1) GEP20135986B (en)
WO (1) WO2010103544A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2804341A1 (en) 2010-07-06 2012-01-12 Navipharm Co., Ltd. Time-delayed sustained release pharmaceutical composition comprising dapoxetine for oral administration
WO2012172413A1 (en) 2011-06-16 2012-12-20 Abbott Healthcare Pvt. Ltd. Pharmaceutical composition comprising a combination of eperisone and diclofenac and process for preparing thereof
KR101156054B1 (en) * 2011-09-05 2012-06-20 주식회사 네비팜 A stable and control-released pharmaceutical composition comprising eperisone
KR101832842B1 (en) * 2012-01-13 2018-02-27 한미약품 주식회사 Pharmaceutical composition with an improved stability comprising eperisone or a pharmaceutically acceptable salt thereof and specific acidifying agent
US9682093B2 (en) 2012-03-30 2017-06-20 Charles R. Drew University Of Medicine And Science Compositions and methods for treating or preventing metabolic syndrome disorders
CN102895206A (en) * 2012-10-31 2013-01-30 中国药科大学 Rhizoma bletillae polysaccharide gastric-floating tablet and preparation method and application thereof
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
KR101497354B1 (en) * 2013-03-29 2015-03-02 초당약품공업 주식회사 Slow release pharmaceutical composition having Eperisone as active ingredient
CN103432093B (en) * 2013-08-31 2015-03-25 西南大学 Pridinol methanesulfonate matrix sustained-release tablet and preparation method thereof
PL2848260T3 (en) * 2013-09-12 2016-09-30 Novel formulations of thiocolchicoside
PL2848261T3 (en) * 2013-09-12 2016-10-31 Pharmaceutical formulations comprising a muscle relaxant and an analgesic combination
EP2848259B1 (en) * 2013-09-12 2016-03-23 Sanovel Ilac Sanayi ve Ticaret A.S. Sustained release pharmaceutical formulations of Thiocolchicoside
CN104688709A (en) * 2015-03-24 2015-06-10 北京世桥生物制药有限公司 Fumaric acid quetiapine composition sustained-release tablet and preparing method thereof
WO2018044020A1 (en) * 2016-08-29 2018-03-08 초당약품공업 주식회사 Method for preparing eperisone sustained release microsphere, and composite preparation of eperisone sustained release microsphere and aceclofenac
TR201720293A2 (en) * 2017-12-13 2019-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Tolperisone and non-selective cox inhibitor combinations
TR201720289A2 (en) * 2017-12-13 2019-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Tolperizon and Selective COX-2 Inhibitor Combinations
TR201819202A2 (en) * 2018-12-12 2020-06-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A COMBINATION CONTAINING ONE MULTIPLE SCLEROSIS AGENT AND AT LEAST ONE MUSCLE RELAXING AGENT
TR201906487A1 (en) 2019-04-30 2020-11-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi PHARMACEUTICAL COMPOSITIONS CONTAINING TOLPERISONE AND NIMESULIDE COMBINATIONS

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0720866B2 (en) * 1987-05-15 1995-03-08 三生製薬株式会社 Transdermal preparation containing eperisone or tolperisone or their salts
JPS6485915A (en) 1987-09-28 1989-03-30 Eisai Co Ltd Hypotensor
US5252588A (en) 1990-04-27 1993-10-12 Sekisui Kagaku Kogyo Kabushiki Kaisha Percutaneously absorbable crosslinked polyvinylpyrrolidone eperisone or tolperisone preparation
JP2626248B2 (en) 1991-04-08 1997-07-02 日本新薬株式会社 Capsule
AT409083B (en) 1999-04-01 2002-05-27 Sanochemia Pharmazeutika Ag PHARMACEUTICAL PREPARATION CONTAINING TOLPERISON FOR ORAL ADMINISTRATION
US6753011B2 (en) 2000-01-14 2004-06-22 Osmotica Corp Combined diffusion/osmotic pumping drug delivery system
KR100433614B1 (en) * 2000-06-16 2004-05-31 주식회사 태평양 Transdermal Preparation Containing Hydrophilic or Salt-form Drug
US6733781B2 (en) 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
US20040224012A1 (en) 2001-10-05 2004-11-11 Pichit Suvanprakorn Topical application and methods for administration of active agents using liposome macro-beads
KR100511492B1 (en) 2002-10-11 2005-08-31 주식회사 태평양 Transdermal preparations comprising eperisone, tolperisone or salts thereof
AT500144A1 (en) 2004-03-05 2005-11-15 Sanochemia Pharmazeutika Ag TOLPERISON-CONTAINING PHARMACEUTICAL PREPARATION WITH CONTROLLABLE ACTIVE INGREDIENTS FOR ORAL ADMINISTRATION
US20060004050A1 (en) 2004-07-02 2006-01-05 Speicher Brian T Compositions and methods for the prevention or treatment of pain and other nervous system disorders
CN101002752A (en) * 2005-09-26 2007-07-25 刘凤鸣 Slow release preparation of tropyone
WO2008004127A2 (en) 2006-04-20 2008-01-10 Sanochemia Pharmazeutika Ag Method for administering tolperisone
HUP0700485A3 (en) * 2007-07-23 2010-01-28 Richter Gedeon Nyrt Pharmaceutical composition with controlled release containing tolperisone

Also Published As

Publication number Publication date
WO2010103544A4 (en) 2011-06-03
EP2405900A2 (en) 2012-01-18
GEP20135986B (en) 2013-12-10
WO2010103544A3 (en) 2011-04-07
WO2010103544A2 (en) 2010-09-16
CN102438597A (en) 2012-05-02

Similar Documents

Publication Publication Date Title
EA201171109A1 (en) NEW COMPOSITION OF THE DELAYED RELEASE OF COMPOUNDS SELECTED FROM THE CLASS OF MINORALEXANTS OF CENTRAL ACTION
WO2012035559A3 (en) Sustained release pharmaceutical compositions comprising pregabalin
AU2014363599B2 (en) Orally disintegrating solid dosage unit containing an estetrol component
EA200901277A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DAPAGLYFLOSINE PROPYLENE GLYCOLHYDRATE
JP2013542247A5 (en)
MX2019011491A (en) Niraparib formulations.
EA201690102A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYLFUMATE FOR INTRODUCTION TO LOW DAILY DOSE
TN2012000421A1 (en) Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
AR070731A1 (en) PHARMACEUTICAL COMPOSITION FOR LITTLE SOLUBLE PHARMACOS
RU2013121788A (en) HIV REPLICATION INHIBITORS
ES2916649T1 (en) Compositions and uses for the treatment of multiple sclerosis
NZ605888A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain
AR075735A1 (en) PHARMACEUTICAL COMPOSITIONS OF IMMEDIATE RELEASE THAT INCLUDE OXYCODONE AND NALOXONE. USE
BR112012021681A2 (en) rifaximin powder, process for preparing it and controlled release compositions containing said rifaximin useful for obtaining a long lasting effect.
ITBO20110012A1 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING RIFAXIMINA AND THEIR USE.
MX2012009079A (en) Extended release formulations of rasagiline and uses thereof.
TN2012000246A1 (en) Pharmaceutical compositions comprising sigma receptor ligands
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
EA200870469A1 (en) NEW, CONTAINING NIMESULIDE, PHARMACEUTICAL COMPOSITIONS WITH LOW DOSE, THEIR RECEPTION AND APPLICATION
TN2013000257A1 (en) Immunosuppressant formulations
MX2021014774A (en) Modified release formulations and uses thereof.
UA89795C2 (en) Pharmaceutical composition comprising temozolomide ester
BR112012020377A8 (en) use of one or more selected from the group consisting of a compound of formula (i), a racemic-diastereomeric mixture and an optical isomer of said compound, and a pharmaceutically acceptable salt and prodrug thereof, method, pharmaceutical composition and treatment kit cachexia and commercial packaging
RU2013157834A (en) COMPOSITIONS FOR SCRIPT INTRODUCTION OF PHYSIOLOGICALLY ACTIVE PRODUCTS
JP2016522235A5 (en)